At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALT Altimmune, Inc.
Post-Mkt 08-12 16:46:10 EDT
2.93
-0.07
-2.33%
盘后2.98
+0.05+1.69%
16:43 EDT
High3.20Low2.92Vol6.01M
Open3.05D1 Closing3.00Amplitude9.33%
Mkt Cap568.42MTradable Cap552.58MTotal Shares194.00M
T/O18.43MT/O Rate3.19%Tradable Shares188.60M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR), Altimmune (ALT) and HCA Healthcare (HCA)
TIPRANKS  ·  00:40
Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR), Altimmune (ALT) and HCA Healthcare (HCA)
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Reuters  ·  00:17
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Altimmune Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12 21:31
Altimmune Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Altimmune Rises on Smaller-than-Expected Quarterly Loss
Reuters  ·  08-12 20:15
Altimmune Rises on Smaller-than-Expected Quarterly Loss
Altimmune Posts Smaller-than-Expected Q2 Net Loss Per Share
Reuters  ·  08-12 19:43
Altimmune Posts Smaller-than-Expected Q2 Net Loss Per Share
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate
Benzinga Earnings  ·  08-12 19:33
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  08-11 18:00
Calendar of U.S. Earnings Expected in the Week Ahead
Altimmune Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview
Reuters  ·  08-10 21:51
Altimmune Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview
Bitcoin holds a resistance break as gold surges and ALT risk builds
Kitco  ·  08-06
Bitcoin holds a resistance break as gold surges and ALT risk builds
Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH
MT Newswires Live  ·  08-03
Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH
Altimmune - 52-Week Data Readout from Performa Phase 3 Trial Anticipated in 2029
THOMSON REUTERS  ·  08-03
Altimmune - 52-Week Data Readout from Performa Phase 3 Trial Anticipated in 2029
Altimmune Initiates Performa Phase 3 Trial of Pemvidutide in Patients with Mash
THOMSON REUTERS  ·  08-03
Altimmune Initiates Performa Phase 3 Trial of Pemvidutide in Patients with Mash
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
GlobeNewswire  ·  07-30
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (GOVX), Incyte (INCY) and Altimmune (ALT)
TIPRANKS  ·  07-29
Analysts’ Opinions Are Mixed on These Healthcare Stocks: GeoVax Labs (GOVX), Incyte (INCY) and Altimmune (ALT)
U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal
Reuters  ·  07-29
U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal
U.S. Stocks on the MOVE-Visa, CMS Energy, Ecolab
Reuters  ·  07-29
U.S. Stocks on the MOVE-Visa, CMS Energy, Ecolab
Barclays says trial data highlights meaningful opportunity for Altimmune in AUD
TIPRANKS  ·  07-29
Barclays says trial data highlights meaningful opportunity for Altimmune in AUD
H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune
TIPRANKS  ·  07-28
H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune
Leerink remains bullish on Altimmune following ‘positive’ AUD trial results
TIPRANKS  ·  07-28
Leerink remains bullish on Altimmune following ‘positive’ AUD trial results
Unusually active option classes on open July 28th
TIPRANKS  ·  07-28
Unusually active option classes on open July 28th

Introduction

Company Name.
Altimmune, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Issue price:
--